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ABSTRACT
Background: The feasibility of the sentinel node mapping in upper tract urothelial cancers (UTUC) was evaluated, using a ra-
diotracer as the mapping material. 
Material and methods: To identify the sentinel lymph nodes, 37 MBq of [99mTc] phytate was injected in five patients with the 
renal pelvis or ureter cancer, who were candidates for ureterectomy and lymphadenectomy. The radiotracer was injected in 
a peritumoral fashion following the surgical exposure of the tumour. The sentinel lymph nodes were detected using a hand-
held gamma probe. 
Results: By intraoperatively injecting the radiotracer immediately after surgical exposure of the tumour, at least one sentinel 
lymph node could be detected in each patient, and the detection rate was 100%. The location of sentinel nodes was in the par-
acaval, renal hill, retro-aortic, para-aortic, common iliac, and external iliac areas, which was dependent on the tumour location. 
No false-negative case was identified.
Conclusions: Sentinel node mapping is feasible in UTUC. Injection technique (intra-vesical approach vs peri-tumoral injection 
after exposure of the tumour) and location of the tumour (proximal vs distal) may affect the technique’s feasibility.
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Introduction 
Urothelial carcinomas can be originated from lower (bladder 
and urethra) or upper (pyelocaliceal cavities and ureter) parts of 
the urinary tract [1]. Bladder carcinomas (lower tract urothelial 
carcinomas) account for 90–95% of the urinary tract malignancies; 
however, the upper urinary tract (UUT) transitional cell carcinoma 
(TCC) is an uncommon type of malignancies and accounts for 
5–10% of urinary tract cancers [2, 3]. Tumours of the ureter are par-
ticularly rare compared to bladder cancer or renal pelvis tumours, 
despite sharing common histopathology and similar risk factors [4].
The most common treatment option for high-grade tumours orig-
inate in the upper ureter and renal pelvis, is nephroureterectomy 
followed by regional lymph node dissection (LND); however, due 
to the low incidence of the upper tract urinary carcinoma (UTUC), 
the indication and extent of LND is not standardized [5]. The 
risk of lymph node involvement increases with the T stage of the 
disease, and up to 60% of UTUCs demonstrate local invasion at 
diagnosis [6]. LND is recommended to be performed based on 
the laterality and tumour location following nephroureterectomy; 
however, due to variable lymphatic drainage and lack of consen-
sus on anatomical boundaries, the potential benefit of routine LND 
on survival or disease recurrence remains controversial [7, 8].
Sentinel lymph node mapping procedure is used for detecting 
the first lymph node in the path of lymphatic drainage of cancers. 
This technique reveals the pathological status of the regional 
lymph nodes for the better staging of the disease, determining the 
treatment strategy, and preventing the unnecessary LND. Senti-
nel lymph node biopsy is routinely performed for breast cancer, 
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the tip of the gamma probe while the probe was pointed to the 
ceiling. All the lymph nodes with ex-vivo count five times higher 
than the background (thigh) were eventually determined as the 
sentinel lymph node. 
After harvesting the detected sentinel lymph nodes, the surgical 
area was searched again to confirm the complete sentinel lymph 
node removal.
Regional lymphadenectomy was performed based on the 
surgeon’s decision to assess the false-negative rate. For the left- 
-sided renal pelvis, upper ureteral, and mid-urethral tumours, the 
lymphadenectomy dissection area covered para-aortic, pre-aortic, 
and inter-aortocaval nodes from the renal hilum to the aortic bifur-
cation. For the right-sided renal pelvis and upper ureteral tumours, 
mid-urethral tumours lymph nodes of the paracaval, precaval, and 
interaortocaval areas from the renal hilum to the aortic bifurcation 
are considered for lymphadenectomy. Common iliac, external iliac, 
obturator, and hypogastric lymph nodes of each side of the pelvic 
are also dissected for mid to distal ureteral tumours.
malignant melanoma, gynaecological, and penile tumours; how-
ever, for other urologic genitourinary carcinomas, it is still under 
investigation [9–14]. 
The present study evaluated the feasibility of sentinel node 
mapping in UTUC using a radiotracer as the mapping material. 
Material and methods
This study was approved by the ethics committee of Mashhad 
University of Medical Sciences under the number 940295. Between 
2016 and 2019, all the admitted UTUC patients at the urology de-
partment of Imam Reza Hospital, Mashhad, Iran, were included. 
All the patients gave their informed consent before inclusion in 
the study. Patients with negative lymph node involvement before 
the surgery, based on clinical and radiological evaluations (cN0, 
cM0) were included. The exclusion criteria were positive lymph 
nodes metastasis and a history of chemotherapy or radiotherapy. 
Radiotracer injection
Following anaesthesia, 37 MBq of [99mTc]phytate in two divided 
doses (0.5 mL each) were used as the radiotracer. In the first four 
patients with TCC of the distal part of the ureter, the radiotracer 
was injected sub-mucosally in the peritumoral area of the tumour 
through ureteroscopy. These patients were excluded from the study 
due to sentinel lymph node detection failure. The injection technique 
was changed in five other patients: the radiotracer was injected 
into two peritumoral sites following the tumour’s exposure (Tab. 1, 
Fig. 1).
Sentinel node biopsy
The mean time between the tracer injection and performing 
intraoperative sentinel lymph node mapping was one hour. Fol-
lowing the excision of the ureter and kidney and before starting 
lymphadenectomy, a hand-held gamma probe (SURGIGUIDE, 
Partonegar Persia) was used to measure the radioactivity and per-
form sentinel node biopsy. The sentinel lymph nodes were defined 
as any lymph node with an in-vivo count of at least ten times higher 
than the background (thigh). These nodes were dissected and 
counted again ex-vivo. The dissected lymph nodes were put on 
Table 1. Detailed data of the included patients















1 M 53 Middle right T3 2.5 Yes Paracaval 3 Yes 1/3 Yes (paracaval)
2 M 74 Proximal Left T1 2.7 Yes Renal hill 2 No No
3 M 40 Renal pelvis  
(proximal)
Right T3 4 × 2 Yes Renal hill 2 No No





5 F 48 Renal pelvis  
(proximal)




SN — sentinel node
Figure 1. Injection of the radiotracer in a patient with mid-urethral 
tumour, after the surgergical exposure of the tumour
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Histopathological investigation
The pathologists examined the excised lymph nodes and 
specimen; all dissected tissues were formalin-fixed, paraffin-em-
bedded, and serially sectioned for haematoxylin-eosin staining. 
The histopathological status of the sentinel nodes was compared 
with the other dissected lymph nodes. 
Evaluated indices (detection rate and false-negative 
rate)
The primary endpoints of the study were sentinel node detection 
rate and false-negative rate (FNR). 
The detection rate was measured as the ratio of all cases with 
at least one detected sentinel node to all included patients. The 
false-negative rate was measured as the ratio of patients with 
involved non-sentinel lymph nodes despite pathologically free 
sentinel lymph nodes to all patients with involved nodes and at 
least one harvested sentinel node [15, 16].
Results
Five patients with renal pelvis or ureter cancer were included; 
four patients were male, and one was female with a mean age of 59. 
The tumour was localized in proximal ureter in two patients, 
distal ureter in one patient, and middle ureter in one patient. 
Demographic data and information regarding the sentinel lymph 
node detection are summarized in Table 1. 
Detection rate 
In all patients with the peritumorally injection of the radiotracer 
following the surgical exposure of the tumour, at least one sentinel 
node was detected. The detection rate was 100% in these five 
patients, and eleven (median = 2) sentinel lymph nodes were 
dissected in total (Fig. 1). 
All the patients with no detected sentinel node were injected 
through the ureteroscopy at two sites around the visible tumour; 
so, the detection rate was zero in UTUC patients with ureteroscopic 
injections; these patients were excluded from the study. 
The detected sentinel nodes were in the paracaval lymph 
nodes (patient 1), renal hilum lymph nodes (patients 2 and 3), retro 
aortic and para-aortic lymph nodes (patient 5), and common iliac 
and external iliac lymph nodes (patient 4). 
False-negative rate
One patient (number 1) had pathological involvement of the 
dissected sentinel lymph node. The detected sentinel nodes were 
in paracaval area (three sentinel nodes), and one showed tumoral 
involvement. Based on the pathology report, the non-sentinel 
paracaval lymph nodes dissected in this patient were also patho-
logically involved.
No lymph node involvement was noted in the remaining four 
patients (no false-negative result).
Discussion
Upper urinary tract TCCs are among the rare types of genitouri-
nary tumours which develop in the renal pelvis and ureter and might 
be associated with bladder cancer. To the authors’ knowledge, they 
evaluated the feasibility of the sentinel node mapping approach for 
the first time in patients with UTUC including, patients with TCCs in 
the proximal, middle, and distal parts of the ureter and also in the 
renal pelvis. They used Tc-99m phytate as the mapping material, 
and no blue dye was used due to the reported adverse reaction to 
the blue dye injection [17, 18]. 
The detection rate in this study was highly dependent on the 
injection method of the radiotracer. In patients with the uretero-
scopic injection of the tracer, no sentinel node could be identified 
intra-operatively. So, these patients were excluded from the study 
and changed the injection technique. In the remaining patients (five 
patients) with radiotracer injection following the tumour exposure 
during the surgery, at least one sentinel node could be identified. 
These results are most likely due to the technical difficulty of injec-
tion through a ureteroscope. The movement of the radiotracer in the 
lymphatic system is reasonably fast, which ensures a successful 
mapping using an intra-operative injection of the tracer [19–21]. 
Although LND is performed for better staging of the tumour, due 
to the low prevalence of UTUC, the curative role of LND continues to 
be debated, and LND is not currently performed in all patients world-
wide. In patients with the T1 stage of the disease, there might be 
a low probability of the LN metastases, and LND does not seem to 
improve the staging. All the current evidence on UTUC is based on 
retrospective studies with a limited study population. To precisely 
determine the indication of LND and its optimal template, which 
varies according to the location of the disease, more extensive 
studies should be performed [22–27]. Although the LND template 
has been studied previously, there is no standardized template for 
LND, and it is dependent on the site of the affected ureter [1, 28].
Based on the present results, sentinel lymph nodes as the 
first lymph nodes which receive the metastatic cells were located 
in the renal hilum, retro-aortic, and para-aortic lymph nodes of the 
patients with TCCs in the proximal part of the left ureter or the left 
renal pelvis. However, in two patients with TCCs in the middle part 
of the right ureter and the right renal pelvis, the detected sentinel 
lymph nodes were in paracaval and right renal hilum lymph nodes. 
The sentinel lymph nodes in one of the study patients with TCC in the 
distal part of the right ureter was in the common iliac and external 
iliac lymph nodes. The present results were in accordance with the 
previous studies in this regard. Kondo et al. [22] proposed that the 
paracaval, retrocaval, and interaortocaval nodes have a higher 
risk of metastases in patients with the right renal pelvis and upper 
two-thirds of the ureter tumours and should be included in the 
LND template. On the other hand, the renal hilum and para-aortic 
nodes in patients with left renal pelvis tumours should be considered 
in the LND template. 
We included only patients with no lymph node involvement 
based on preoperative imaging; however, these modalities have 
shown limited accuracy for preoperative LN staging or identifying 
patients with LN invasion [29, 30]. LND in patients with UTUC 
is highly surgeon-dependent due to inaccurate prediction tools, 
and sentinel lymph node mapping might be of value to find the 
metastatic status of the regional lymph nodes. This study showed 
that sentinel node could be detected in all the UTUC patients with 
the intraoperative injection of the radiotracer mapping, and sentinel 
lymph node mapping might be a feasible method in patients with 
tumours in different parts of the ureter or renal pelvis. However, 
more extensive studies (preferably multicentral) are needed before 
any definitive conclusion. 
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The major limitation of the present study was the low sample 
size due to the low incidence of UTUC. However, to the authors’ 
knowledge, this study is the first study on intraoperative sentinel 
lymph node mapping in UTUC tumours, which obtained promising 
results.
Conclusions
Sentinel node mapping is feasible in UTUC. Injection technique 
(intra-vesical approach vs peri-tumoral injection after exposure of 
the tumour) and location of the tumour (proximal vs distal) might 
affect the technique’s feasibility. 
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